MX2018007796A - Compuestos de fenilimidazol. - Google Patents

Compuestos de fenilimidazol.

Info

Publication number
MX2018007796A
MX2018007796A MX2018007796A MX2018007796A MX2018007796A MX 2018007796 A MX2018007796 A MX 2018007796A MX 2018007796 A MX2018007796 A MX 2018007796A MX 2018007796 A MX2018007796 A MX 2018007796A MX 2018007796 A MX2018007796 A MX 2018007796A
Authority
MX
Mexico
Prior art keywords
phenylimidazole compound
compound
phenylimidazole
hyperlipidemia
obesity
Prior art date
Application number
MX2018007796A
Other languages
English (en)
Inventor
Koushi Iwata
Tadao Shibutani
Satoshi Kido
Mori Daisuke
Yoshioka Hidenori
Nakata Hikaru
Ishimaru Akiko
Original Assignee
Otsuka Pharma Factory Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Factory Inc filed Critical Otsuka Pharma Factory Inc
Publication of MX2018007796A publication Critical patent/MX2018007796A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se provee un compuesto (agente quimioterapéutico) eficaz para la prevención y tratamiento de hiperlipidemia, obesidad, o similares; un compuesto de fenilimidazol o una sal farmacéuticamente aceptable del mismo representado por la siguiente fórmula (1): (ver Fórmula).
MX2018007796A 2015-12-25 2016-10-25 Compuestos de fenilimidazol. MX2018007796A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015254016 2015-12-25
PCT/JP2016/081633 WO2017110237A1 (ja) 2015-12-25 2016-10-25 フェニルイミダゾール化合物

Publications (1)

Publication Number Publication Date
MX2018007796A true MX2018007796A (es) 2019-05-23

Family

ID=59089969

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018007796A MX2018007796A (es) 2015-12-25 2016-10-25 Compuestos de fenilimidazol.
MX2021010182A MX2021010182A (es) 2015-12-25 2016-10-25 Compuestos de fenilimidazol.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010182A MX2021010182A (es) 2015-12-25 2016-10-25 Compuestos de fenilimidazol.

Country Status (22)

Country Link
US (1) US10570117B2 (es)
EP (2) EP4023640A1 (es)
JP (3) JP6828899B2 (es)
KR (2) KR102176505B1 (es)
CN (2) CN113200962A (es)
AR (2) AR107191A1 (es)
AU (2) AU2016378154B2 (es)
CA (1) CA3009485C (es)
DK (1) DK3401310T3 (es)
ES (1) ES2913488T3 (es)
HK (2) HK1257221A1 (es)
HU (1) HUE058875T2 (es)
MX (2) MX2018007796A (es)
MY (1) MY196907A (es)
PH (1) PH12018501100A1 (es)
PL (1) PL3401310T3 (es)
PT (1) PT3401310T (es)
RU (1) RU2715712C2 (es)
SG (1) SG11201804310VA (es)
TW (2) TWI780557B (es)
WO (1) WO2017110237A1 (es)
ZA (1) ZA201803419B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022024649A1 (ja) 2020-07-30 2022-02-03 株式会社大塚製薬工場 感冒剤及び抗ウイルス剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134983A (en) * 1975-03-03 1979-01-16 Merck & Co., Inc. 3-amino-2-or-propoxyaryl substituted imidazoles
US4642311A (en) * 1975-03-03 1987-02-10 Merck & Co., Inc. β-adrenergic blocking imidazolylphenoxy propanolamines
CA1075689A (en) * 1976-07-23 1980-04-15 John J. Baldwin Substituted imidazoles, their preparation and use
AU518569B2 (en) 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
US4443446A (en) 1980-05-30 1984-04-17 University Of Georgia Research Foundation, Inc. Use of psychoactive drugs as vaginal contraceptives
US5861359A (en) * 1995-07-25 1999-01-19 Fmc Corporation Herbicidal phenylmethoxphenyl heterocycles
PL2280706T3 (pl) * 2008-05-14 2013-05-31 Otsuka Pharma Factory Inc Kompozycje zawierające pochodne benzenu aktywujące lipazę lipoproteinową
DK2394996T3 (en) * 2009-02-04 2016-08-01 Otsuka Pharma Factory Inc Phenylimidazolforbindelser
EP3293177A4 (en) * 2015-04-07 2018-12-12 Guangdong Zhongsheng Pharmaceutical Co., Ltd Tyrosine kinase inhibitor and pharmaceutical composition comprising same

Also Published As

Publication number Publication date
CN108430977B (zh) 2021-06-08
TW201722937A (zh) 2017-07-01
JPWO2017110237A1 (ja) 2018-10-11
RU2715712C2 (ru) 2020-03-03
US10570117B2 (en) 2020-02-25
AU2016378154B2 (en) 2020-08-13
RU2020105627A3 (es) 2022-02-22
CA3009485C (en) 2020-08-25
JP6828899B2 (ja) 2021-02-10
DK3401310T3 (da) 2022-05-02
CN108430977A (zh) 2018-08-21
HK1257221A1 (zh) 2019-10-18
TWI721057B (zh) 2021-03-11
EP3401310B1 (en) 2022-04-06
KR20200108118A (ko) 2020-09-16
RU2020105627A (ru) 2020-02-17
CN113200962A (zh) 2021-08-03
AR107191A1 (es) 2018-03-28
ZA201803419B (en) 2019-08-28
HK1257353A1 (zh) 2019-10-18
EP3401310A1 (en) 2018-11-14
HUE058875T2 (hu) 2022-09-28
AU2016378154A1 (en) 2018-06-07
AR123029A2 (es) 2022-10-26
WO2017110237A1 (ja) 2017-06-29
EP3401310A4 (en) 2019-05-29
ES2913488T3 (es) 2022-06-02
JP2023017055A (ja) 2023-02-02
US20180354930A1 (en) 2018-12-13
AU2020260426B2 (en) 2021-10-07
KR20180098285A (ko) 2018-09-03
TW202124376A (zh) 2021-07-01
PL3401310T3 (pl) 2022-07-04
KR102176505B1 (ko) 2020-11-09
JP2021042250A (ja) 2021-03-18
RU2018127016A3 (es) 2020-01-30
MY196907A (en) 2023-05-09
MX2021010182A (es) 2022-10-25
KR102318395B1 (ko) 2021-10-27
BR112018012326A2 (pt) 2018-12-04
PH12018501100A1 (en) 2019-01-28
SG11201804310VA (en) 2018-06-28
TWI780557B (zh) 2022-10-11
AU2020260426A1 (en) 2020-11-26
RU2018127016A (ru) 2020-01-30
EP4023640A1 (en) 2022-07-06
PT3401310T (pt) 2022-06-02
CA3009485A1 (en) 2017-06-29
JP7224674B2 (ja) 2023-02-20

Similar Documents

Publication Publication Date Title
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
PH12017501523A1 (en) Selective bace1 inhibitors
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
MA39749A (fr) Dérivés de pipéridine-dione
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
MA39956A (fr) Analogues du benzomorphane et leur utilisation
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
PH12019501955A1 (en) Tri-cycle compound and applications thereof
TN2019000211A1 (en) Antitumoral compounds
PH12018500282A1 (en) Cgrp receptor antagonists
MY193239A (en) Novel b-lactamase inhibitors
PH12018500999A1 (en) Sodium channel blocker
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
AU2016330503A8 (en) Therapeutic compounds and methods of use thereof
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
PH12018501100A1 (en) Phenylimidazole compound
MX2020004972A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar ataque de ausencia o epilepsia que muestra ataque de ausencia.
IL265976A (en) Use of a compound, pharmaceutical preparation and therapeutic method for the treatment or prevention of convulsions
EP3556363A4 (en) USE OF A CARBAMATE COMPOUND FOR PREVENTING, RELIEVING OR TREATING PRURITUS